These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33431149)

  • 1. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands.
    de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ
    Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes.
    de Boer PT; Backer JA; van Hoek AJ; Wallinga J
    BMC Med; 2020 Jan; 18(1):11. PubMed ID: 31931789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program.
    Zeevat F; Crépey P; Dolk FCK; Postma AJ; Breeveld-Dwarkasing VNA; Postma MJ
    Value Health; 2021 Jan; 24(1):3-10. PubMed ID: 33431150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.
    Hart RJ; Stevenson MD; Smith MJ; LaJoie AS; Cross K
    JAMA Pediatr; 2018 Jan; 172(1):e173879. PubMed ID: 29114729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model.
    Gerlier L; Lamotte M; Grenèche S; Lenne X; Carrat F; Weil-Olivier C; Damm O; Schwehm M; Eichner M
    Appl Health Econ Health Policy; 2017 Apr; 15(2):261-276. PubMed ID: 27943165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
    Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
    Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
    Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
    Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Sandmann FG; van Leeuwen E; Bernard-Stoecklin S; Casado I; Castilla J; Domegan L; Gherasim A; Hooiveld M; Kislaya I; Larrauri A; Levy-Bruhl D; Machado A; Marques DFP; Martínez-Baz I; Mazagatos C; McMenamin J; Meijer A; Murray JLK; Nunes B; O'Donnell J; Reynolds A; Thorrington D; Pebody R; Baguelin M
    Vaccine; 2022 Feb; 40(9):1306-1315. PubMed ID: 35109968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    BMC Med; 2017 Sep; 15(1):166. PubMed ID: 28882149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
    Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study.
    Baguelin M; Camacho A; Flasche S; Edmunds WJ
    BMC Med; 2015 Oct; 13():236. PubMed ID: 26459265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.